Correction: Vertex Hepatitis C Drug
Correction: Vertex Hepatitis C Drug CAMBRIDGE, Mass. — In a story Jan. 11 about Vertex Pharmaceuticals Inc. and its hepatitis C drug, The Associated Press misstated when the company will seek regulatory approval for the drug. Approval will be requested in the second half of 2010, not 2009. Correction: Vertex Hepatis C DrugCuris reports smaller loss in 3Q and says it expects lower spending for full year 2009Vertex says most patients on telaprevir for hepatitis C had undetectable virus levels in trialVertex says telaprevir created immune response in most patients with hepatitis CVertex says most patients who took hepatitis C drug had undetectable virus levels in trialVertex Pharma books larger 3rd-quarter loss as collaboration revenue falls, costs increaseBiogen Idec says Tysabri sales grew 21 pct, lower amortization expenses aided 3rd-qtr profitBiogen 3Q profit beats views on smaller charges CAMBRIDGE, Mass. — Biogen Idec says its profit jumped 34 percent in the third quarter due to lower amortization costs and increased sales of its multiple sclerosis drug Tysabri. Tips for women travelers: Don’t forget the dental flossTips for women travelers: Don’t forget the floss CAMBRIDGE, Mass. — What do dental floss, shower caps and Bounce dryer sheets have in common? |
|